默认为title标签的值,后台可管理

We respect your privacy. Please consent to all cookies when you visit our website. Refer to our "Privacy Policy"for more information on how we handle personal data.

  • pc.jpg Frame13213177591.jpg

  • a1banpc02.jpg a1banph02.jpg
    Make Blood Coagulation No Longer A Concern
    GS1191 , a gene therapeutic product for hemophilia A totally developed by Gritgen, has got IND approval and initiated Phase I trials in P.R. China.

  • a1banpc03.jpg a1banph03.jpg
    Empower Science for Human
    Healthier Life
    Seeking Truth, Responsibility, Cooperation, Excellence

About Us

Our Team

Founded by the top-notch biologist Dr. Yi Rao in 2019, Gritgen is dedicated to make "Great Science for human health" and committed to becoming a global biotech by innovative research. 

  • 2019

    Founded in

  • 3

    sites

  • 8600sq.m.

    cGMP

  • 3

    Technology Platforms

Platform and Pipeline

Adeno associated virus (AAV), not readily to cause an immune reaction and integrated into the genome of the target cell, is a safe and broadly applicable vector for gene therapy. The gene, capsid, promotor and enhancer are the key components of a vector. We developed propriatary, next-generation AAV capsid platform and high effient promotor and enhancer system. Combining with the fundamental understanding of the genetics and underlying biology of diseases, Gritgen has developed a robust pipeline spanning from rare diseases to common diseases. 

Culture

Vision
Innovative Gene therapy better the lives of all mankind
Value
Seeking Truth, Excellence
Cooperation, Responsibility